,,ii  #aahth ,,congress  #ast ,session  
,s4 #bcg  ,,in ,,the ,,senate ,,of ,,the
 ,,united ,,states  ,february #b1       
#bjbc,ms4 ,smith 7for herself1 ,mr4     
,booker1 ,mrs4 ,gillibrand1 ,mr4        
,hickenlooper1 ,mr4 ,kaine1 ,mr4 ,king1 
,mr4 ,merkley1 ,mr4 ,padilla1 ,mr4      
,schatz1 and ,ms4 ,stabenow7 introduced 
the following bill2 which was read twice
 and referred to the ,committee on      
,health1 ,education1 ,labor1 and        
,pensions  ,a ,,bill  ,to preserve      
access to abortion medications4  #a4    
,short title ,this ,act may be cited as 
the ,protecting ,access to ,medication  
,abortion ,act of #bjbc4  #b4           
,modification of ,,rems  7a7 ,in general
 ,the ,secretary of ,health and ,human  
,services 7referred to in this section  
as the ,secretary7 shall ensure that the
 risk evaluation and mitigation strategy
 under section #eje-a of the ,federal   
,food1 ,drug1 and ,cosmetic ,act 7#ba   
,u4,s4,c4 #cee-a7 that applies to       
mifepristone-- 7#a7 does not have an    

in-person dispensing requirement for    
such drug2  7#b7 allows for patient     
access to prescriptions for such drug   
via telehealth2 and  7#c7 allows all    
pharmacies that are certified to        
dispense such drug to1 at minimum1      
dispense and mail such drug to patients4
  7b7 ,modifications ,nothing in        
subsection 7a7 shall be construed to    
prevent the ,secretary from approving a 
modification to the risk evaluation and 
mitigation strategy for mifepristone    
based on sound scientific evidence and  
in accordance with section #eje-a7;h7 of
 the ,federal ,food1 ,drug1 and         
,cosmetic ,act 7#ba ,u4,s4,c4           
#cee-a7;h771 except that any            
modifications to such risk evaluation   
and mitigation strategy made after      
,january #c1 #bjbc1 shall be in         
accordance with the requirements under  
paragraphs 7#a71 7#b71 and 7#c7 of      
subsection 7a71 unless the ,secretary1  
based on sound scientific evidence and  
in accordance with section #eje-a of    

such ,act 7#ba ,u4,s4,c4 #cee-a71       
determines that a risk evaluation and   
mitigation strategy for mifepristone is 
no longer necessary4  7c7 ,clarification
 ,nothing in subsection 7a7 shall be    
construed to limit the authority of the 
,secretary to impose the requirements   
described in paragraphs 7#a71 7#b71 and 
7#c7 of such subsection to a risk       
evaluation and mitigation strategy under
 section #eje-a of the ,federal ,food1  
,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4
 #cee-a7 for any drug other than        
mifepristone4  7d7 ,definition ,in this 
section1 the term mifepristone means    
mifepristone that is-- 7#a7 approved    
under subsection 7c7 or 7j7 of section  
#eje of the ,federal ,food1 ,drug1 and  
,cosmetic ,act 7#ba ,u4,s4,c4 #cee72    
7#b7 indicated for medical abortion2 and
  7#c7 subject to a risk evaluation and 
mitigation strategy under section #eje-a
 of the ,federal ,food1 ,drug1 and      
,cosmetic ,act 7#ba ,u4,s4,c4 #cee-a74